These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6986226)

  • 1. The effect of mineralocorticoid administration on urine free dopamine in man.
    Oates NS; Perkins CM; Lee MR
    Clin Sci (Lond); 1980 Jan; 58(1):77-82. PubMed ID: 6986226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of mineralocorticoid activity on transtubular potassium gradient, urinary [K]/[Na] ratio, and fractional excretion of potassium.
    Chacko M; Fordtran JS; Emmett M
    Am J Kidney Dis; 1998 Jul; 32(1):47-51. PubMed ID: 9669423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid activity and the excretion of an oral potassium load in normal man.
    Hené RJ; Koomans HA; Rabelink AJ; Boer P; Dorhout Mees EJ
    Kidney Int; 1988 Nov; 34(5):697-703. PubMed ID: 3199680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fludrocortisone and spironolactone on sodium and potassium losses in secretory diarrhea.
    Wenzl HH; Fine KD; Santa Ana CA; Porter JL; Fordtran JS
    Dig Dis Sci; 1997 Jan; 42(1):119-28. PubMed ID: 9009126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary prostasin: a candidate marker of epithelial sodium channel activation in humans.
    Olivieri O; Castagna A; Guarini P; Chiecchi L; Sabaini G; Pizzolo F; Corrocher R; Righetti PG
    Hypertension; 2005 Oct; 46(4):683-8. PubMed ID: 16172430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volume-pressure relationships during development of mineralocorticoid hypertension in man.
    Wenting GH; Man in 't Veld AJ; Verhoeven RP; Derkx FH; Schalekamp DH
    Circ Res; 1977 May; 40(5 Suppl 1):I163-70. PubMed ID: 858175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the plasma levels of atrial natriuretic peptides during mineralocorticoid escape in man.
    Cappuccio FP; Markandu ND; Buckley MG; Sagnella GA; Shore AC; MacGregor GA
    Clin Sci (Lond); 1987 May; 72(5):531-9. PubMed ID: 2953526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and urine dopamine in man given sodium chloride in the diet.
    Oates NS; Ball SG; Perkins CM; Lee MR
    Clin Sci (Lond); 1979 Mar; 56(3):261-4. PubMed ID: 477209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potassium supplementation ameliorates mineralocorticoid-induced sodium retention.
    Krishna GG; Kapoor SC
    Kidney Int; 1993 May; 43(5):1097-103. PubMed ID: 8510388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human atrial natriuretic polypeptide during escape from mineralocorticoid excess in man.
    Miyamori I; Ikeda M; Matsubara T; Okamoto S; Koshida H; Morise T; Takeda R
    Clin Sci (Lond); 1987 Oct; 73(4):431-6. PubMed ID: 2959429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid-induced blood pressure, electrolyte, and hormone changes, and reversal with spironolactone, in healthy men.
    Nicholls MG; Ramsay LE; Boddy K; Fraser R; Morton JJ; Robertson JI
    Metabolism; 1979 May; 28(5):584-93. PubMed ID: 449700
    [No Abstract]   [Full Text] [Related]  

  • 12. Response of plasma aldosterone to fludrocortisone in primary hyperaldosteronism and other forms of hypertension.
    Padfield PL; Allison ME; Brown JJ; Ferriss JB; Fraser R; Lever AF; Luke RG; Robertson JI
    Clin Endocrinol (Oxf); 1975 Sep; 4(5):493-500. PubMed ID: 1175311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential blood pressure and metabolic effects of 9 alpha-fluorocortisol in man.
    Whitworth JA; Saines D; Thatcher R
    Clin Exp Pharmacol Physiol; 1983; 10(3):351-4. PubMed ID: 6354534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial natriuretic peptide during mineralocorticoid escape in the human.
    Zimmerman RS; Edwards BS; Schwab TR; Heublein DM; Burnett JC
    J Clin Endocrinol Metab; 1987 Mar; 64(3):624-7. PubMed ID: 2950127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary aldosterone to creatinine ratio in cats before and after suppression with salt or fludrocortisone acetate.
    Djajadiningrat-Laanen SC; Galac S; Cammelbeeck SE; van Laar KJ; Boer P; Kooistra HS
    J Vet Intern Med; 2008; 22(6):1283-8. PubMed ID: 18775055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on mineralocorticoid 'escape' in cirrhosis.
    Wilkinson SP; Smith IK; Moodie H; Poston L; Williams R
    Clin Sci (Lond); 1979 May; 56(5):401-6. PubMed ID: 477224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation of the renin-aldosterone system and refractoriness to the sodium-retaining action of mineralocorticoid during starvation in man.
    Boulter PR; Spark RF; Arky RA
    J Clin Endocrinol Metab; 1974 Feb; 38(2):248-54. PubMed ID: 4812620
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of DOCA and 9 alpha-fludrocortisone on renal renin content and production.
    Menting J; Morgan T; Barrett G; Di Nicolantonio R
    Clin Exp Pharmacol Physiol; 1987 Mar; 14(3):259-62. PubMed ID: 3311501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of mineralocorticoid replacement therapy on renal acid-base homeostasis in adrenalectomized patients.
    Sebastian A; Sutton JM; Hulter HN; Schambelan M; Poler SM
    Kidney Int; 1980 Dec; 18(6):762-73. PubMed ID: 7206460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in plasma renin activity after administration of spironolactone.
    Maebashi M; Yoshinaga K
    Jpn Circ J; 1967 Mar; 31(3):435-9. PubMed ID: 6072372
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.